GBC
News & Events
GBC Exhibiting at ADLM 2025 Conference in Chicago (July 28 – July 31)
Whether you are developing a new diagnostic device and need samples for R&D, are a startup navigating the complex regulatory environment, or conducting post-market or health […]
Global BioClinical is Attending the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (5/31/25 to 6/2/205)
ASCO 2025 is almost here! May 31 – June 2 | Chicago, IL at McCormick Place Convention Center Global BioClinical is attending the American Society of […]
GBC Attending Life Science Innovation Northwest (LSINW) 2025 in Seattle, WA (4/23/25 to 4/24/25)
Global BioClinical is looking forward to attending Life Science Innovation Northwest (LSINW) 2025 next Wednesday, April 23rd and 24th, at the Seattle Convention Center! #LSINW2025 is […]
Teal Health Unveils Landmark Study Results Showing Teal Wand™ Self-Collected Samples Match Clinician Collected Samples
San Francisco, CA – March 18, 2025 – Teal Health, a women’s health company on a mission to eradicate cervical cancer by bringing at-home cervical cancer screening to […]
GBC Partners with Boudicca DX to Become a One Stop Global Shop for Strategy and Execution for Medical Device & In Vitro Diagnostic Companies
See press release here: https://lnkd.in/e8tBZd6Z February 12, 2025. Boudicca DX a global precision medicine consulting firm withoperations in the United States (Boudicca DX, LLC) and Ireland […]
MUSE Microscopy Showcasing SmartPath MUSE Technology
IRVINE, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) — MUSE Microscopy, Inc. (the “Company”, “we”, “our”) is thrilled to announce the introduction of SmartPath MUSE Technology™ (SmartPath), […]
Teal Health Completes Clinical Trial at Record Speed and Receives FDA Breakthrough Designation for Its At-Home Cervical Cancer Screening Device, the Teal Wand™
In the last 6 months, Teal Health and their clinical study partners exceeded their study enrollment numbers months ahead of schedule, produced strong clinical performance data, […]
OpGen Submits De Novo Request to the U.S. FDA for Unyvero Urinary Tract Infection (UTI) Panel
ROCKVILLE, Md., April 18, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help […]
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection (UTI) Panel
ROCKVILLE, Md., Dec. 13, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help […]
InfanDx Tackles Early Detection of Hypoxic Ischemic Encephalopathy
InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, has completed the validation of metabolic biomarker […]
Contact Us
